Following the successful issuance by Viva Biotech of USD 180 million of secured convertible bonds on February 11, 2020, JunHe assisted Viva Biotech Investment Management Limited ("VIB", stock symbol: 1873.HK), a wholly-owned subsidiary of Viva Biotech Holdings, to successfully issue USD 280 million of secured convertible bonds on December 30, 2020.
As a structure-based drug discovery (CRO) supplier, Viva Biotech operates a world-leading early stage drug discovery technology platform and a systematic, scientific, modular incubation platform with highly technical capabilities. It owns numerous world leading technologies. Viva Biotech has developed an extensive business model, which combines the traditional cash for equity (CFS) model with the proprietary cash for equity (EFS) model. On the EFS model, Viva Biotech provides drug discovery and/or incubation services to selected customers and promising biotechnology companies in exchange for equity or economic interests. Viva Biotech was successfully listed on the Main Board of the Stock Exchange of Hong Kong on May 9, 2019 and was included on the Hang Seng Hong Kong-Listed Biotechnology Index in December 2019. JunHe was a legal consultant for Viva Biotech's Hong Kong listing project.
JunHe acted as issuer and Chinese legal counsel to Viva Biotech in this project. JunHe’s team undertook PRC legal due diligence and reviewed and provided PRC legal opinions with a high degree of quality and efficiency within a very tight time frame. JunHe provided a whole-process legal service with respect to the PRC legal issues involved in this project. They demonstrated a consistent efficient, rigorous, and stable work style with a meticulous, professional service attitude. Viva Biotech and other intermediary agencies unanimously praised the high standard of work provided by JunHe.